Appl. No. 09/917,236 Amdt. dated November 19, 2003 Reply to Final Office Action of June 18, 2003

REMARKS

Entry of the preceding amendments and favorable reconsideration are respectfully requested in view the preceding amendments and the following comments.

The claims have been limited to attenuating or reducing hair growth, which is clearly and completely supported by Applicants' examples. The prostaglandin EP-3 receptor agonist is also limited to a hair growth inhibiting prostaglandin EP-3 receptor agonist, which is amply exemplified in Applicants' disclosure.

The rejection of claims 1 to 20 "under 35 U.S.C. 112, first paragraph" is respectfully traversed. The limitation of the claims to attenuating or reducing hair growth and the further limitation of the receptor agonist to a "hair growth inhibiting prostaglandin EP-3 receptor agonist" directly addresses and overcomes the adverse holding with regard to "commensurate in scope", as well as the position regarding "undue experimentation". Virtually no experimentation is required; if the receptor agonist is a "hair growth inhibiting prostaglandin EP-3 receptor agonist", no experimentation whatsoever is necessary. To find out whether it meets that definition is merely a routine matter. The breadth of the claims has thus been significantly reduced, and the basis for the adverse holding has been overcome.

With regard to "enablement", that issue is also completely overcome by the further limitation of claims to subject matter supported by and exemplified in Applicants' specification.

The essence of the questioned enablement is directed to "stopping the growth of hair", which has been deleted from claim 1, from which all other claims are at least ultimately dependent. Please note that the language of dependent claims 15 and 16 is also instantly similarly limited.

The issue of enablement is clearly directed to "stopping the growth of hair", which no longer appears in any of Applicants' claims.

Applicants have found, disclosed and exemplified growth inhibiting prostaglandin EP-3 receptor agonists, to which all of the instantly asserted claims are presently limited.

Having overcome all outstanding grounds of rejection, favorable action on the merits and allowance of all of Applicants' claims are in order and are respectfully solicited.

The entry of this amendment does not involve any new issues and requires no further search or examination.

Respectfully submitted,

JACOBSON HOLMAN PLLC

Date: November 20, 2003

(202) 638-6666

400 Seventh Street, N.W.

Washington, D.C. 20004

HBJ/IMA/cmd

Atty. Dkt. No.: 61/P66901US0

By Mulberbag for Harvey B. Jacobson, Jr.
Registration No. 20,851